Skip to Main Content

Author Details

David P Curley
The Warren Alpert Medical School of Brown University
2001
20
18
PMIDPaper TitleJournal TitlePublished Year
25584893mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.Cancer Cell2015
25656429Altered mental status and tachycardia.J Emerg Med2015
25805116Communication of Vital Signs at Emergency Department Handoff: Opportunities for Improvement.Ann Emerg Med2015
25027202Boarding is associated with higher rates of medication delays and adverse events but fewer laboratory-related delays.Am J Emerg Med2014
25385281Evaluation of a clinical tool for early etiology identification in status epilepticus.Epilepsia2014
22172720β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.Cancer Cell2011
20048081Characterization of melanoma cells capable of propagating tumors from a single cell.Cancer Res2010
19282848Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.Nat Genet2009
18353136A new mechanism of release from senescence: suppression of p16INK4a by beta-catenin.Pigment Cell Melanoma Res2008
17575131Loss of xeroderma pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-deficient mice.Cancer Res2007
16676322Characterization of melanocyte-specific inducible Cre recombinase transgenic mice.Genesis2006
17145863Epigenetic silencing of novel tumor suppressors in malignant melanoma.Cancer Res2006
15784726Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype.Blood2005
16116483FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.Oncogene2005
15256420Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.Blood2004
15607963MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.Cancer Cell2004
12781364PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.Cancer Cell2003
12124172CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).Cancer Cell2002
12060771PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.Proc Natl Acad Sci U S A2002
11719379The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways.Blood2001
  • 1 - 20 of 20

Recommended Authors

Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 4
Michael P O'Connell
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 2
Vijay Walia
National Center for Toxicological Research
Career Start Year 2006
Number of shared co-authors 1
Donghui Cheng
University of California los angeles
Career Start Year 2003
Number of shared co-authors 0
Chi-Ping Day
Center for Cancer Research, National Cancer Institute
Career Start Year 2002
Number of shared co-authors 3
Daniel Zingg
Netherlands Cancer Institute
Career Start Year 2001
Number of shared co-authors 1
Christopher J Howlett
Western University
Career Start Year 1999
Number of shared co-authors 0
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 0
Sandra Burkett
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 0
Yaoqi Alan Wang
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 1
Lianbo Yu
The Ohio State University
Career Start Year 1997
Number of shared co-authors 0
Andrew E Aplin
Thomas Jefferson University
Career Start Year 1996
Number of shared co-authors 3
Ashani T Weeraratna
Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Career Start Year 1992
Number of shared co-authors 4
James DeGregori
University of Colorado Anschutz Medical Campus
Career Start Year 1991
Number of shared co-authors 0
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 1
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 5
Lionel Larue
Institut Curie, PSL Research University, INSERM U1021
Career Start Year 1987
Number of shared co-authors 4
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 1
Brent W Zanke
University of Toronto
Career Start Year 1987
Number of shared co-authors 0
Louis Gaboury
Institute for Research in Immunology and Cancer (IRIC), University of Montreal
Career Start Year 1986
Number of shared co-authors 0
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 2
Grant A McArthur
University of Melbourne
Career Start Year 1986
Number of shared co-authors 3
David E Fisher
Cutaneous Biology Research Center, Mass. General Hospital, Harvard Medical School
Career Start Year 1983
Number of shared co-authors 6
Phuong Nguyen
Hoag Memorial Hospital Presbyterian
Career Start Year 1983
Number of shared co-authors 0
Colin R Goding
Ludwig Institute for Cancer Research, University of Oxford
Career Start Year 1983
Number of shared co-authors 0
David J Adams
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 3
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 0
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 2
Frank McCormick
Frederick National Laboratory for Cancer Research
Career Start Year 1975
Number of shared co-authors 0
Norman E Sharpless
National Cancer Institute
Career Start Year 1945
Number of shared co-authors 4

Collaborators

Marcus Bosenberg
Yale School of Medicine
Co-authored papers 8
Shan W Liu
Massachusetts General Hospital, Harvard Medical School
Co-authored papers 2
Yuchiao Chang
Massachusetts General Hospital
Co-authored papers 2
Donna Neuberg
Co-authored papers 2
Brian J P Huntly
University of Cambridge
Co-authored papers 2
Jiraporn Sri-On
Vajira Hospital, Navamindradhiraj University
Co-authored papers 1
Jong Woo Lee
Brigham and Women's Hospital
Co-authored papers 1
Jason Gotlib
Stanford University School of Medicine
Co-authored papers 1
David L Rimm
Yale University School of Medicine
Co-authored papers 1
Nabeel Bardeesy
Massachusetts General Hospital
Co-authored papers 1
Daniel J DeAngelo
Dana-Farber Cancer Institute
Co-authored papers 1
Sekhar Duraisamy
Co-authored papers 1
Glenn Merlino
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 1
Nancy A Speck
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 1
Carlos A Camargo
Massachusetts General Hospital and Harvard Medical School
Co-authored papers 1
Joel S Weissman
Center for Surgery and Public Health, Brigham and Women's Hospital
Co-authored papers 1
Andrea O Rossetti
Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne
Co-authored papers 1
Sara J Singer
Stanford University School of Medicine.
Co-authored papers 1
Timothy J Ley
Washington University School of Medicine
Co-authored papers 1
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 1
Frank W Drislane
Beth Israel Deaconess Medical Center, Harvard University
Co-authored papers 1
Michael B Westover
Beth Israel Deaconess Medical Center
Co-authored papers 1
M Raza Zaidi
Northwell Health Cancer Institute
Co-authored papers 1
Michael A Davies
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Lynda Chin
Co-authored papers 1
Release 1.2